Vincent van der Wel

Vincent holds degrees in Medicine, Business Studies, and Health Economics. This mix gives Vincent a good understanding of the clinical impact of treatments on clinicians and patients and the economic impact of drug development on payers, shareholders, and investors. 

As the founder of Orfenix, Vincent has contributed to the incorporation and funding of three public-private partnerships currently developing treatments for rare diseases. Additionally, Vincent has supported over 15 projects advancing drug development within the academic community.

Vincent works closely with academic initiatives to advance academic drug development, such as the platform Medicine for Society and the national hub for drug repurposing and rare disease Rare-NL.

Vincent actively contributes to scientific research on public-private partnerships, developing orphan medicine and pricing. At the Amsterdam UMC, he supports PhD students in executing drug development projects and their research. 

Vincent holds several certificates in regulatory affairs and clinical development. He has hands-on experience with regulatory interactions at national and European levels. Vincent has obtained orphan designations and worked on multiple scientific advice and protocol assistance procedures.